US panel endorses 2nd vaccine for kids' virus By MIKE STOBBE (AP Medical Writer) From Associated Press. Picked up by e-News & Earthlink.net 6.25.08

[Guest guest]

Oops! Sorry about that---I accidentally clicked on send before I pasted the

article. ~~Ruth/REU

===================

US panel endorses 2nd vaccine for kids' virus

By MIKE STOBBE (AP Medical Writer)

From Associated Press

June 25, 2008 4:31 PM EDT

ATLANTA - A federal advisory panel has endorsed a second vaccine to combat a

common and potentially fatal virus that causes diarrhea and vomiting in

children.

The new two-dose vaccine for infants, made by GlaxoKline, was licensed by

the Food and Drug Administration in April. The vaccine advisory committee agreed

Wednesday that it should be added to the recommended vaccines for infants, as

well as the three-dose vaccine made by Merck & Co. and approved in 2006.

Both vaccines are given orally to prevent rotavirus, which causes 67,000

hospitalizations of children under 5 each year in the U.S., but only about 30

deaths. Worldwide, it kills an estimated 500,000 children a year.

Rotavirus is a leading cause of severe diarrhea in infants and children, but is

perhaps better known as the cause of vomiting that often strikes children in the

winter.

The vaccine advisory panel's recommendations typically are adopted by the

government, which issues vaccination guidelines to doctors and hospitals.

The committee voiced no preference for one vaccine over the other.

The new two-dose version can be completed in four months, compared to six months

for the older version. Both are estimated to cost about $200. Government

endorsement of a vaccine often means insurance companies will pay for it.

Wide use of the older vaccine is credited with reducing the severity of

rotavirus over the past year.

The virus follows a pattern similar to flu season, but the 2007-08 season was

the mildest in 15 years, the Centers for Disease Control and Prevention said.

Copyright 2008 The Associated Press. All rights reserved. This material may not

be published, broadcast, rewritten or redistributed.

ATLANTA - A federal advisory panel has endorsed a second vaccine to combat a

common and potentially fatal virus that causes diarrhea and vomiting in

children.

The new two-dose vaccine for infants, made by GlaxoKline, was licensed by

the Food and Drug Administration in April. The vaccine advisory committee agreed

Wednesday that it should be added to the recommended vaccines for infants, as

well as the three-dose vaccine made by Merck & Co. and approved in 2006.

Both vaccines are given orally to prevent rotavirus, which causes 67,000

hospitalizations of children under 5 each year in the U.S., but only about 30

deaths. Worldwide, it kills an estimated 500,000 children a year.

Rotavirus is a leading cause of severe diarrhea in infants and children, but is

perhaps better known as the cause of vomiting that often strikes children in the

winter.

The vaccine advisory panel's recommendations typically are adopted by the

government, which issues vaccination guidelines to doctors and hospitals.

The committee voiced no preference for one vaccine over the other.

The new two-dose version can be completed in four months, compared to six months

for the older version. Both are estimated to cost about $200. Government

endorsement of a vaccine often means insurance companies will pay for it.

Wide use of the older vaccine is credited with reducing the severity of

rotavirus over the past year.

The virus follows a pattern similar to flu season, but the 2007-08 season was

the mildest in 15 years, the Centers for Disease Control and Prevention said.

Copyright 2008 The Associated Press. All rights reserved. This material may not

be published, broadcast, rewritten or redistributed.

ATLANTA - A federal advisory panel has endorsed a second vaccine to combat a

common and potentially fatal virus that causes diarrhea and vomiting in

children.

The new two-dose vaccine for infants, made by GlaxoKline, was licensed by

the Food and Drug Administration in April. The vaccine advisory committee agreed

Wednesday that it should be added to the recommended vaccines for infants, as

well as the three-dose vaccine made by Merck & Co. and approved in 2006.

Both vaccines are given orally to prevent rotavirus, which causes 67,000

hospitalizations of children under 5 each year in the U.S., but only about 30

deaths. Worldwide, it kills an estimated 500,000 children a year.

Rotavirus is a leading cause of severe diarrhea in infants and children, but is

perhaps better known as the cause of vomiting that often strikes children in the

winter.

The vaccine advisory panel's recommendations typically are adopted by the

government, which issues vaccination guidelines to doctors and hospitals.

The committee voiced no preference for one vaccine over the other.

The new two-dose version can be completed in four months, compared to six months

for the older version. Both are estimated to cost about $200. Government

endorsement of a vaccine often means insurance companies will pay for it.

Wide use of the older vaccine is credited with reducing the severity of

rotavirus over the past year.

The virus follows a pattern similar to flu season, but the 2007-08 season was

the mildest in 15 years, the Centers for Disease Control and Prevention said.

==================================

Copyright 2008 The Associated Press. All rights reserved. This material may not

be published, broadcast, rewritten or redistributed.

[Guest guest]

Oops! Sorry about that---I accidentally clicked on send before I pasted the

article. ~~Ruth/REU

===================

US panel endorses 2nd vaccine for kids' virus

By MIKE STOBBE (AP Medical Writer)

From Associated Press

June 25, 2008 4:31 PM EDT

ATLANTA - A federal advisory panel has endorsed a second vaccine to combat a

common and potentially fatal virus that causes diarrhea and vomiting in

children.

The new two-dose vaccine for infants, made by GlaxoKline, was licensed by

the Food and Drug Administration in April. The vaccine advisory committee agreed

Wednesday that it should be added to the recommended vaccines for infants, as

well as the three-dose vaccine made by Merck & Co. and approved in 2006.

Both vaccines are given orally to prevent rotavirus, which causes 67,000

hospitalizations of children under 5 each year in the U.S., but only about 30

deaths. Worldwide, it kills an estimated 500,000 children a year.

Rotavirus is a leading cause of severe diarrhea in infants and children, but is

perhaps better known as the cause of vomiting that often strikes children in the

winter.

The vaccine advisory panel's recommendations typically are adopted by the

government, which issues vaccination guidelines to doctors and hospitals.

The committee voiced no preference for one vaccine over the other.

The new two-dose version can be completed in four months, compared to six months

for the older version. Both are estimated to cost about $200. Government

endorsement of a vaccine often means insurance companies will pay for it.

Wide use of the older vaccine is credited with reducing the severity of

rotavirus over the past year.

The virus follows a pattern similar to flu season, but the 2007-08 season was

the mildest in 15 years, the Centers for Disease Control and Prevention said.

Copyright 2008 The Associated Press. All rights reserved. This material may not

be published, broadcast, rewritten or redistributed.

ATLANTA - A federal advisory panel has endorsed a second vaccine to combat a

common and potentially fatal virus that causes diarrhea and vomiting in

children.

The new two-dose vaccine for infants, made by GlaxoKline, was licensed by

the Food and Drug Administration in April. The vaccine advisory committee agreed

Wednesday that it should be added to the recommended vaccines for infants, as

well as the three-dose vaccine made by Merck & Co. and approved in 2006.

Both vaccines are given orally to prevent rotavirus, which causes 67,000

hospitalizations of children under 5 each year in the U.S., but only about 30

deaths. Worldwide, it kills an estimated 500,000 children a year.

Rotavirus is a leading cause of severe diarrhea in infants and children, but is

perhaps better known as the cause of vomiting that often strikes children in the

winter.

The vaccine advisory panel's recommendations typically are adopted by the

government, which issues vaccination guidelines to doctors and hospitals.

The committee voiced no preference for one vaccine over the other.

The new two-dose version can be completed in four months, compared to six months

for the older version. Both are estimated to cost about $200. Government

endorsement of a vaccine often means insurance companies will pay for it.

Wide use of the older vaccine is credited with reducing the severity of

rotavirus over the past year.

The virus follows a pattern similar to flu season, but the 2007-08 season was

the mildest in 15 years, the Centers for Disease Control and Prevention said.

Copyright 2008 The Associated Press. All rights reserved. This material may not

be published, broadcast, rewritten or redistributed.

ATLANTA - A federal advisory panel has endorsed a second vaccine to combat a

common and potentially fatal virus that causes diarrhea and vomiting in

children.

The new two-dose vaccine for infants, made by GlaxoKline, was licensed by

the Food and Drug Administration in April. The vaccine advisory committee agreed

Wednesday that it should be added to the recommended vaccines for infants, as

well as the three-dose vaccine made by Merck & Co. and approved in 2006.

Both vaccines are given orally to prevent rotavirus, which causes 67,000

hospitalizations of children under 5 each year in the U.S., but only about 30

deaths. Worldwide, it kills an estimated 500,000 children a year.

Rotavirus is a leading cause of severe diarrhea in infants and children, but is

perhaps better known as the cause of vomiting that often strikes children in the

winter.

The vaccine advisory panel's recommendations typically are adopted by the

government, which issues vaccination guidelines to doctors and hospitals.

The committee voiced no preference for one vaccine over the other.

The new two-dose version can be completed in four months, compared to six months

for the older version. Both are estimated to cost about $200. Government

endorsement of a vaccine often means insurance companies will pay for it.

Wide use of the older vaccine is credited with reducing the severity of

rotavirus over the past year.

The virus follows a pattern similar to flu season, but the 2007-08 season was

the mildest in 15 years, the Centers for Disease Control and Prevention said.

==================================

Copyright 2008 The Associated Press. All rights reserved. This material may not

be published, broadcast, rewritten or redistributed.